We are live on
!
Find out more
PR
PSP Research Portfolio holdings
AUM
$188M
This Fund
S&P 500
This Quarter
Est. Return
+18.09%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$114M
AUM Growth
–
Cap. Flow
+$110M
Cap. Flow
% of AUM
96.55%
Top 10 Holdings %
Top 10 Hldgs %
65.84%
Holding
85
New
85
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
+$70.3M |
| 2 |
Legend Biotech
LEGN
|
+$699K |
| 3 |
ACLX
Arcellx
ACLX
|
+$656K |
| 4 |
Amylyx Pharmaceuticals
AMLX
|
+$601K |
| 5 |
Mineralys Therapeutics
MLYS
|
+$594K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
iShares 0-3 Month Treasury Bond ETF
SGOV
$104B
| $70.3M | 61.41% |
+700,000
| New | +$70.3M |
|
2
Praxis Precision Medicines
PRAX
$10.5B
| $584K | 0.51% |
+1,982
| New | +$369K |
|
3
Travere Therapeutics
TVTX
$6.33B
| $584K | 0.51% |
+15,272
| New | +$497K |
|
4
Tyra Biosciences
TYRA
$1.56B
| $575K | 0.5% |
+21,853
| New | +$401K |
|
5
Pharvaris
PHVS
$2.6B
| $569K | 0.5% |
+20,511
| New | +$494K |
|
6
Jazz Pharmaceuticals
JAZZ
$16.2B
| $554K | 0.48% |
+3,258
| New | +$499K |
|
7
Celldex Therapeutics
CLDX
$3.19B
| $553K | 0.48% |
+20,368
| New | +$536K |
|
8
CG Oncology
CGON
$6.95B
| $552K | 0.48% |
+13,293
| New | +$550K |
|
|
BLTE
9
Belite Bio
BLTE
$6.31B
| $551K | 0.48% |
+3,443
| New | +$408K |
|
10
Ascendis Pharma A/S
ASND
$16.4B
| $550K | 0.48% |
+2,579
| New | +$533K |
|
|
APLS
11
DELISTED
Apellis Pharmaceuticals
APLS
| $549K | 0.48% |
+21,866
| New | +$513K |
|
|
TERN
12
DELISTED
Terns Pharmaceuticals
TERN
| $548K | 0.48% |
+13,560
| New | +$313K |
|
13
Revolution Medicines
RVMD
$46.2B
| $547K | 0.48% |
+6,872
| New | +$451K |
|
|
CNTA
14
DELISTED
Centessa Pharmaceuticals
CNTA
| $547K | 0.48% |
+21,879
| New | +$554K |
|
15
BridgeBio Pharma
BBIO
$15.5B
| $546K | 0.48% |
+7,140
| New | +$469K |
|
16
Nurix Therapeutics
NRIX
$2.77B
| $545K | 0.48% |
+28,713
| New | +$412K |
|
17
Arcutis Biotherapeutics
ARQT
$3.16B
| $544K | 0.48% |
+18,716
| New | +$479K |
|
18
Kodiak Sciences
KOD
$2.47B
| $543K | 0.47% |
+19,418
| New | +$398K |
|
19
Immunome
IMNM
$3.27B
| $542K | 0.47% |
+25,245
| New | +$443K |
|
20
Aurinia Pharmaceuticals
AUPH
$2.2B
| $542K | 0.47% |
+33,953
| New | +$481K |
|
21
Mirum Pharmaceuticals
MIRM
$6.01B
| $541K | 0.47% |
+6,854
| New | +$492K |
|
22
Halozyme
HALO
$12.2B
| $540K | 0.47% |
+8,026
| New | +$540K |
|
23
EyePoint Inc
EYPT
$430M
| $540K | 0.47% |
+29,530
| New | +$418K |
|
24
Alkermes
ALKS
$8.25B
| $539K | 0.47% |
+19,280
| New | +$577K |
|
25
Ionis Pharmaceuticals
IONS
$10.5B
| $538K | 0.47% |
+6,800
| New | +$512K |
|
Similar funds
IJWM
TCPG
KCPT
DWS
RMSCM
AWP
AIMA
CFP
PSP Research's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for PSP Research, which disclosed 85 positions worth $114M. Its ten largest holdings account for 66% of the portfolio.
Its largest position is iShares 0-3 Month Treasury Bond ETF: 700,000 shares worth $70.3M.
By sector, the portfolio is most concentrated in Healthcare at 39% of assets.
- PSP Research's largest Q4 2025 buy was iShares 0-3 Month Treasury Bond ETF: 700,000 shares worth $70.3M.
- PSP Research's ten largest holdings make up 66% of its $114M portfolio in Q4 2025.
- PSP Research disclosed 85 positions in Q4 2025, its first 13F filing on record.
Based on PSP Research's 13F filing for Q4 2025, filed 6 Feb 2026.